Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Do you offer IV iron first line to women with iron deficiency anemia from heavy menstrual bleeding?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

I offer first-line IV iron because oral iron cannot keep up with the losses from heavy menstrual bleeding, and the majority can't tolerate it. I routinely give a gram of LMW iron dextran in one hour, Feraheme (not ferumoxytol generic) 1,020 mg in 30 minutes, or ferric derisomaltose 1 gram in 30 minu...

Has your practice changed to PLEX-free initial therapy for iTTP?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester School of Medicine and Dentistry

I am not. The reason being is that caplacizumab is not on formulary at my institution and so implementing PLEX rapidly while obtaining caplacizumab (which typically arrives in 24-48 hours) is my current practice.If I had caplacizumab on formulary, I would utilize it as it was utilized in the MAYARI ...

Are there any alternative, hypofractionated RT courses for patients with DLBCL that can be used during the COVID-19 pandemic?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · David Geffen School of Medicine at UCLA

ILROG recently came out with guidelines pasted below: Synopsis of ILROG Recommendations for Administering Radiotherapy for Hematological Malignancies During Emergency Conditions of the COVID-19 Pandemic • We are facing an increased demand for RT to substitute or complement systemic therapy deemed i...

How do you approach the second-line treatment for a patient with high-risk myeloma relapse early post-autoHCT after Dara-RVD induction?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · Memorial Sloan Kettering Cancer Center

Depending on the nature of the relapse, I would salvage with DCEP, or carfilzomib-based triplet (KCyD, KPd) with ciltacel as the next step.

When do you opt to administer IV iron for patients with heart failure who may also have anemia of chronic disease or at risk for iron deposition disease?

1 Answers

Mednet Member
Mednet Member
Cardiology · University of Puerto Rico School of Medicine

I do not hesitate to administer IV iron in a patient with heart failure (chronic inflammation) if serum ferritin levels are <30 ng/ml and TSAT is under 20%. This is the only way, besides blood transfusions, to improve Hgb levels in this patient population.

How do you counsel patients on the risk of thromboembolic complications with use of immunotherapy in NSCLC?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · UC San Diego Moores Cancer Center

Patients with metastatic lung cancer are at increased risk of thromboembolic events with an estimated frequency of 13.9% (Connolly et al., PMID 23026639). Preclinical data show that PD-1/PD-1 pathway blockade may lead to increased levels of pro-inflammatory cytokines and T cell driven progression an...

How do you decide between blinatumomab or traditional chemotherapy in combination with TKI for upfront treatment of adult patients with Ph + ALL?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Washington

This question is likely inspired by the recent publication of a "chemotherapy-free induction and consolidation first-line treatment" for adults with Ph+ ALL (Foà et al., PMID 33085860; GIMEMA LAL2116). The authors reported relatively high rates of MRD- remissions by bone marrow BCR-ABL1 RT-PCR and i...

When testing for patients with symptoms of MPN, do you prefer to do JAK2 cascade testing or a leukemia NGS testing panel?

3 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

Genetic testing with regard to the MPN can be usefully employed both diagnostically and prognostically. With respect to diagnosis, if an MPN is suspected based on symptoms such as aquagenic pruritis, ocular migraine, erythromelalgia, or the occurrence of an unexplained thrombosis, the first laborato...

What is your approach to managing iron overload in children with transfusion-dependent beta thalassemia who have adherence challenges or toxicity with standard chelation regimens?

2 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Weill Cornell Medical College

I would divide the adherence issues into two populations. The younger children where a caregiver is responsible for administering the chelation, and adolescents where caregivers have passed on the responsibility to the patient. For the former, adherence is reinforced with an explanation of the possi...

What approaches can we take to initiate therapy and improve survival rates in patients with HLH?

3
2 Answers

Mednet Member
Mednet Member
Infectious Disease · UT Southwestern School of Medicine

At our institution, we have comprised a multidisciplinary team to help treat these patients. The team or "HLH task force" as we like to call ourselves is comprised of a clinical immunologist, rheumatologist, dermatologist, critical care physician, hepatologist, BMT attending/hematologist, infectious...